The company’s focus will be on progressing the clinical validation of its idiopathic pulmonary fibrosis treatment.

Insilico Medicine, whose Hong Kong IPO application lapsed in 2024, is still considering going public in the city, said ...

Alongside new steps in its therapeutic pipeline—and a new push into laboratory robotics—Insilico Medicine has raised $110 ...

Insilico Medicine Inc. is considering an initial public offering after securing funding at a valuation of more than $1 ...

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced today that it has successfully secured a $110 million Series E ...

Insilico Medicine, a clinical-stage biotechnology company pioneering generative AI for drug discovery and development, ...

DeepSeek's artificial intelligence breakthrough has led to an "avalanche" of interest in Chinese tech firms over recent ...

Rentosertib is designed to treat IPF by targeting Traf2- and NCK-interacting kinase (TNIK), a serine/threonine kinase whose activation plays a crucial role in cellular processes that include signal ...

Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, recently announced that its breakthrough drug candidate for idiopathic pulmonary ...

ISM001-055 was shown to have attenuated cellular senescence through the suppression of various aging processes, thus showing potential as a senomorphic drug.

Insilico Medicine has raised $110 million in Series E funding for its artificial intelligence-powered drug discovery ...